Breaking News

Amgen Recalls Lots of Aranesp

August 14, 2014

Prefilled syringes outside U.S. have potential presence of visible particulates

Amgen initiated a voluntary recall on June 26th for nine packaged lots of Aranesp (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed in a small number of syringes during a routine quality check. The lots are being recalled as a precautionary measure, and to date, there have been no adverse events reported attributed to the presence of these particles.
The FDA has determined that health implications related to the particles would vary, depending on route of administration, amount of particulate matter injected, size of the particles, and the patient's underlying medical condition, which may elicit inflammatory and allergic responses, and may be life-threatening.
In the U.S., Aranesp is indicated for the treatment of anemia associated with chronic renal failure, or in patients with non-myeloid malignancies with chemotherapy induced anemia. Aranesp distributed in the U.S. is not impacted by this recall.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks